Dr. Avinash De Sousa.  State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general.

Slides:



Advertisements
Similar presentations
MEDICATION ASSISTED ADDICTION TREATMENT: APPROPRIATE USE DAS Quarterly Provider Meeting Louis E. Baxter, Sr., M.D., FASAM Medical Director-DAS President.
Advertisements

DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED STUDY OF EFFECTIVENESS OF IMPLANTABLE NALTREXONE (PRODETOXONE) FOR TREATMENT OF HEROIN ADDICTION (Interim analysis)
Outpatient Treatment Ellen A. Ovson, M.D. Medical Director
GENERALIZED ANXIETY DISORDER IN PRIMARY CARE Curley Bonds, MD Medical Director Didi Hirsch Mental Health Services Professor & Chair Charles R. Drew University.
TB recurrence & treatment B 陳名揚. Successful treatment more than one drug to which the organisms are susceptible appropriate doses take drugs regularly.
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
An Introduction to Diagnosis and Treatment of Alcoholism Marc A. Schuckit, M.D. Copyright Alcohol Medical Scholars Program1.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Alcoholism and Substance Abuse. Focus Alcoholism.
Alcohol Interventions: What the research tells us Professor Colin Drummond.
TREATMENT CENTRE.  Principles of treatment  treatment goals - abstinence and harm reduction  Types of treatment  medical treatment  psychological.
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Implementing NICE guidance February 2011 NICE clinical.
Copyright Alcohol Medical Scholars Program1 SUBSTANCE USE DISORDERS IN GERIATRIC PATIENTS Steven H. Madonick, M.D. Yale University School of Medicine New.
Copyright Alcohol Medical Scholars Program1 Pathological Gambling and Alcohol Use Disorders Timothy W. Fong MD UCLA Gambling Studies Program Alcohol Medical.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Addiction & Alcoholism. I. Addiction and its Two Key Forms A. Addiction: a condition in which an individual requires the use of a drug or the participation.
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
©AMSP Suicidal Behavior, Alcohol, and Alcohol Use Disorders Timothy W. Lineberry, M.D. Assistant Professor, Psychiatry Mayo Clinic.
IMA MENTAL HEALTH INITIATIVE DEADDICTION PROJECT Dr. DINESH NARAYANAN CO-CHAIRMAN,IMA MENTAL HEALTH NATIONAL CO-ORDINATOR,IMA DE-ADDICTION PROJECT Dr.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
From screening into treatment: Implementation solutions for Alcoholism therapy Thomas R. Kosten MD JH Waggoner Chair and Professor of Psychiatry & Neuroscience.
Experience in developing a tool using the CSSA as a model Kyle M. Kampman M.D. Professor Department of Psychiatry Perelman School of Medicine University.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.
Treatment for Adolescents With Depression Study (TADS)
OPIOID SUBSTITUTION THERAPY
Emotional and Psychiatric Barriers to Addressing HCV Joan E. Zweben, Ph.D. Executive Director: 14 th Street Clinic and East Bay Community Recovery Project.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
ACAMPROSATE Efficacy Results from Three Pivotal Efficacy Trials Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and.
Raymond F. Anton, MD for The COMBINE Study Research Group
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
A. EPIDEMIC RESEARCH Greece took part via ΕΚΤΕPN: I. In 2002 in a European survey of student population (HBSC-WHO) II. In 2003 in a world wide survey of.
Medical and Specialist Interventions in Alcohol Dependence Peter Rice, Consultant Psychiatrist, NHS Tayside.
Medication Partnership Project The Horsham Clinic Change Team = BJ Sellman; Team Leader Dr. Michael Frost Dates = 5/22/12 to present.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
BACLOFEN AS AN ADJUNCT PHARMACOTHERAPY FOR THE MAINTENANCE OF ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS WITH ESTABLISHED LIVER DISEASE Lynn Owens 1, Abi.
® Changes in Opioid Use Over One Year in Patients with Chronic Low Back Pain Alejandra Garza, Gerald Kizerian, PhD, Sandra Burge, PhD The University of.
Evidence Based Medicine Pharmacological Treatment of Alcohol Dependence.
TB physicians’ perspectives on barriers to deliver brief counseling interventions (BCI) within routine tuberculosis services: A qualitative study on a.
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
After the ED Alcohol & Drug Treatment Options Dr Mark Daglish Director of Addiction Psychiatry Royal Brisbane & Women’s Hospital.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
Medicines that interact with alcohol See “Guidance on the administration of medicines to inpatients believed to have consumed alcohol ”
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.
Specialist service provision. Who is involved in specialist services? Statutory services –Run by NHS and Social Care, these deliver medical and psychosocial.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
The introduction of a routine offer of relapse prevention pharmacotherapy following successful alcohol withdrawal: A quality improvement project in a 20.
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
Medication-Assisted Therapy at Coleman Profession Services
Addiction & Alcoholism
Pharmacological and Behavioral
Treatments for Addiction
Alcoholism and unhealthy use
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Pharmacologic Interventions for Unhealthy Drinking
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
How Should We Select and Define Trial Estimands
Presentation transcript:

Dr. Avinash De Sousa

 State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general hospital with a large psychiatric set up.

 No major research available on long term management till last five years.  Few doctors interested in specializing in addiction medicine.  Indian culture and alcohol dependence.

 Cheaper alternative to Naltrexone, Acamprosate and Topiramate.  Alcoholism is a very rampant problems and most patients are the sole bread winners.  Abstinence is very important for work.  Lack of aided psychiatric services.

 Though cheaper – few psychiatrists are comfortable with usage.  Side effects are rare – hepatotoxicity or neuropathy.  Complicated alcohol withdrawals are common in our practice.  Disulfiram induced confusion or psychosis.

 Three open randomized trials ( ) Naltrexone VS Disulfiram Acamprosate VS Disulfiram Topiramate VS Disulfiram  Conditions in the study were similar to routine clinical practice in India.  All patients – underwent detoxification.  Randomized but open study.

 Age between years.  DSM-IV criteria for alcohol dependence.  All had a stable and supportive family environment.  One responsible family member.  Importance of supervised Disulfiram therapy

 Other substance use disorders other than Nicotine Dependence.  Any co-morbid psychiatric disorder.  Any medical condition that would interfere with compliance.  Elevated liver functions.  Previous treatment with the 2 drugs of the study.

 Subjects informed about the study and the drugs involved.  Need for a family member to be present on regular follow up.  Importance of psychoeducation in Disulfiram therapy.

 Addiction Severity Index.  Severity of Alcohol Dependence Scale.  Scale to measure the 3 parameters of craving frequency, duration and intensity – (Anton).  Baseline liver function tests.  Calendar to record alcohol consumption.

 50mg of Naltrexone once a day.  250mg of Disulfiram once a day.  666mg of Acamprosate thrice daily.  50mg Topiramate thrice daily.  NTX and DSF taken as a single daily dose in the morning after breakfast with a family member to observe that the patient takes the medicine.

 Weekly for the first 3 months.  Fortnightly till the end of the study.  Transport paid by us – other incentive offered.  Supportive group psychotherapy – once a week – less structured than in a classical de-addiction programme – emphasis on compliance.

 Sertraline mg and  Escitalopram 5-10mg in case of depression.  Duloxetine 20-40mg per day in the Topiramate study.  Zolpidem 5-10mg at night in case of insomnia.  No benzodiazepines were prescribed.

 Accumulated days of abstinence.  Days until the first relapse (defined as consuming more than 5 alcoholic drinks or 40gm alcohol in 24 hours).

 Craving measures.  GGT measured every 3 months.  Discontinuation of treatment.  Drop out from the study

 All three drugs were well tolerated.  Larger studies across diverse populations of patients are needed to replicate and strengthen these results.  Family support in India is strong – exploiting this resource is a must in the successful use of Disulfiram.

 Disulfiram superior to Naltrexone in elderly alcoholics. (Journal of Pakistan Psychiatric Society 2009)  Disulfiram superior to Naltrexone in adolescent alcohol dependence patients. (Journal of Substance Use 2006)  Disulfiram superior to Naltrexone in female alcoholics. (unpublished work)

 Disulfiram versus a Combined Naltrexone and Acamprosate regime  Does Acamprosate addition enhance Disulfiram therapy.  Disulfiram and Psychotherapy. (All studies would be complete by )

 The Helsinki Disulfiram study.  Disulfiram superior to Acamprosate.  OLITA Study.  Other small but important studies.

 Open studies rather than a blinded ones. Hypothetically a bias may have been introduced.  No laboratory marker used to assess compliance.  Good primary support group leading to fewer drop outs.  Stringent inclusion criteria.

 Incorporating Disulfiram into psychotherapy.  Disulfiram in patients with comorbid psychiatric disorders.  Where does Disulfiram stand today in the modern pharmacotherapy of alcoholism.

 Disulfiram is a treatment option that cannot be ignored.  Psychiatrists worldwide need to be trained.  Oral Disulfiram VS Long acting Naltrexone or Naltrexone implants  Effective compliance monitoring.

 The Stapleford Conference and its organizers.  My parents who have taught me most of my psychiatry.  My country that gives me enough freedom and patients who trust me fully.  Everyone here who made me feel at home.